Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PDE4NPD

Financiado

Cerrado

Parasite specific cyclic nucleotide phosphodiesterase inhibitors to target Negle...

Parasite specific cyclic nucleotide phosphodiesterase inhibitors to target Neglected Parasitic Diseases This project aims to unite global efforts to target the highly druggable class of enzymes called cyclic nucleotide phosphodiesterases (PDEs) in the fight for neglected parasitic diseases (NPD). It will establish a drug discovery p... ver más

28/02/2018

STICHTING VU

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

STICHTING VU No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 11 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-02-28 No tenemos la información de la convocatoria

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

STICHTING VU

0.00€ | Lider

IOTA PHARMACEUTICALS LTD

N.D. | Participante

UNIKENT

N.D. | Participante

UNIVERSITY OF GLASGOW

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NMTRYPI New Medicines for Trypanosomatidic Infections 8M€ Cerrado

REUSE4MALARIA Drug Repurposing for Malaria Chemoprotection 146K€ Cerrado

SAF2015-65740-R OPTIMIZACION DEL POTENCIAL TERAPEUTICO DE LAS PROTEIN QUINAS... 194K€ Cerrado

SUBUN Engineering substrate based inhibitors of Plasmodium SUB1 a... 197K€ Cerrado

TRYPOBASE Nucleobase derivatives as drugs against trypanosomal disease... 4M€ Cerrado

NPsVLCD Natural Product Inspired Therapies for Leishmaniasis and Cha... 213K€ Cerrado

Líder del proyecto

STICHTING VU No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto This project aims to unite global efforts to target the highly druggable class of enzymes called cyclic nucleotide phosphodiesterases (PDEs) in the fight for neglected parasitic diseases (NPD). It will establish a drug discovery platform, PDE4NPD, that combines phenotypic screening with efficient target-centric drug discovery, including target validation, various strategies for compound screening, PDE hit and lead optimization, safety and toxicology assessments and evaluation of anti-parasitic activity. The platform will make use of the target class expertise that the participating SMEs have gained when developing drugs for human and parasite PDEs, while all public partners offer proven experience in the field of NPD. The SMEs will adopt and progress existing PDE inhibitors that are in different stages of the drug discovery pipeline (i.e., target validation, hit and lead optimization). The current portfolio of inhibitors have clinical potential for treating sleeping sickness, Chagas' disease and leishmaniasis. Finding novel hits and leads for the PDEs that are associated with helminth diseases is also foreseen. The platform is open for targeting other NPD, and a broad panel of phenotypic screens (including malaria) is available to test PDE inhibitors. The phenotypic screening is performed by world-renowned groups, including two institutes in endemic countries. By capturing human and parasite PDE-related data in annotated chemogenomics databases, PDE-4-NPD will achieve the knowledge accumulation that is typical for target-centric approaches, thereby making the NPD drug development more efficient and enabling the SMEs to take advantage of the molecular understanding that is key for developing new medicines. The PDE4NPD platform constitutes an ideal basis for creating fruitful collaborations with both public and private partners word-wide.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores